Clinical Trial Update: A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension [Phase 2]

View source ↗

Summary

Long-term (12-month) Phase 2 study evaluating safety, tolerability and efficacy of LCZ696 (sacubitril/valsartan) in essential hypertension. Results were posted …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Hypertension

Drugs mentioned

• LCZ696 (sacubitril/valsartan) (sacubitril/valsartan)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Essential Hypertension | Phase 2 | Status: COMPLETED | Results posted: 2015-10-21